Are you Ready? ArcheMedX platform serves as an early warning detection, says CEO

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/ComicSans)
(Image: Getty/ComicSans)

Related tags: ArcheMedX, Clinical trial sites, Risk

ArcheMedX’s new digital platform aims to reduce the risks and costs associated with underperforming clinical trials by analyzing the behavior of project teams and site personnel.

ArcheMedX, a provider of operational intelligence and workforce readiness solutions, launched the new digital platform, Ready, at this year’s DIA Global Annual Meeting.

According to the company, Ready is currently being used by contract research organizations (CROs), sponsors, and other clinical trial stakeholders.

The platform is used to evaluate “the readiness of project teams and site personnel, detect which staff or sites are most likely to struggle, and focus critical resources to improve preparedness and reduce the risks and costs associated with underperforming sites,”​ said Joel Selzer, ArcheMedX co-founder and CEO.

Selzer described Ready as a platform “that enables clinical operations leaders to evaluate and improve the preparedness of project teams and site personnel.”

“The specific and actionable insights delivered by the platform serve as an early warning detection system to identify risks sooner, ensure resources are more effectively deployed, and enhance staff and site performance,”​ he told us.

Selzer explained that Ready analyzes project teams and site personnel behavior “as they engage in personalized learning experiences.”

“The rich behavioral data generated as they engage in the platform enables Ready to assess their individual mindset and readiness across potential areas of risk,” ​he said, explaining that the platform correlates and visualizes this data against benchmarks to provide insights and recommendations.

Related news

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-May-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us


View more